IPO News | JINGADI Hong Kong Stock Exchange

The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on December 21, Jiinga Technology (Shaoxing) Co., Ltd. (abbreviation: Jiinga) submitted a listing application to the main board of the Hong Kong Stock Exchange, with CCB International and CMBC Capital as co-sponsors. According to the prospectus, Jiinga is a leading precision medicine company in China, deeply embedding AI capabilities into every core link in the biomarker value chain. Based on the self-developed multi-omics platform, combined with basic large-scale models and intelligent AI, the company has built a full chain of capabilities from discovery, verification, product development to commercial implementation of multi-omics biomarkers and targets. As a result, the company provides three major solutions for hospitals, pharmaceutical and biotechnology companies, medical research institutions, etc.: accurate diagnosis, enabling drug development, and clinical research and transformation.